Form 4: Dolby Director Rollins Trades 1,000 Shares

Dolby Laboratories Director Emily Rollins reported a transaction involving 1,000 shares of Class A Common Stock on April 1, 2026.

Summary

• Director Emily Rollins of Dolby Laboratories, Inc. (DLB) engaged in a transaction on April 1, 2026.
• The transaction involved the disposition of 1,000 shares of Class A Common Stock.
• The sale price for these shares was $60.08 per share.
• Following this transaction, Rollins beneficially owns 12,541 shares of Class A Common Stock.
• This transaction was made pursuant to a written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The transaction is a routine sale by a director under a 10b5-1 plan, with no immediate indication of significant positive or negative implications for the company's stock.

Negatives

• Director Emily Rollins sold 1,000 shares of Class A Common Stock.

Future Outlook

The filing does not contain forward-looking statements or guidance.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. This particular filing indicates a sale by a director, which is a common event and often executed under pre-arranged trading plans like Rule 10b5-1 to avoid insider trading concerns.

Stakeholder Impact

• Shareholders: The sale of shares by a director may be interpreted by some shareholders as a signal, though the execution under a 10b5-1 plan mitigates concerns about insider knowledge.
• Management: This transaction is a standard reporting requirement and does not directly impact other management personnel.

Key Dates

Keywords

Form 4, SEC Filing, Insider Trading, Dolby Laboratories, DLB, Class A Common Stock, Stock Sale, Rule 10b5-1